| http://www.w3.org/ns/prov#value | - What: Shares of Furiex Pharmaceuticals (UNKNOWN: FURX.DX ) , a biopharmaceutical company developing drugs to treat a myriad of problems including irritable bowel syndrome, acute bacterial skin and skin structure infections, and type 2 diabetes, more than doubled, gaining as much as 165%, after reporting positive results from its two late-stage studies of eluxadoline for patients with diarrhea-pred
|
